Mucos Pharma Gmbh & Co.

Mucos Emulsiongesellschaft M.b.h.

Karl Ransberger

Gerhard Stauder

Rudolf Kunze

Friedrich-Wilhelm Dittmar

The use of at least one hydrolytic enzyme and at least one flavonoid shows better activity than &agr;-interferon or ribavirin in the treatment of diseases caused by hepatitis C viruses.

Treatment of hepatitis C virus infection using a protease and a flavonoid

The present invention relates to the use of hydrolytic enzymes for the prophylaxis of spontaneous abortion in pregnant women in need thereof with habitual idiophathic abortion in their anamneses.

Use of hydrolytic enzymes for the prophylaxis of spontaneous abortion in

Methods for induction of the tumor necrosis factor, TNF, with at least one of the catabolic enzymes pancreatin, bromelain, papain, lipase, amylase, trypsin, and chymotrypsin are provided.

Process of using catabolic enzymes for induction of tumor necrosis

The therapy approaches known so far for the treatment of the acquired immune deficiency syndrome (AIDS) and its precursors (LAS and ARC) and the secondary diseases related thereto such as opportunistic infections and malignant tumours are either directed against the proliferation of the virus in the body or against the pathogenic organisms of the opportunistic infections or they are selected from the known agents against malignant tumours. So far all therapies did not have any significant success. The new use of catabolic enzymes for the therapy of AIDS and its precursors (LAS and ARC) is made available, with which completely unexpected successes can be achieved in the improvement of the condition of the patient.

Growing community of inventors

Seeshaupt, Germany

Karl Ransberger